This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Vivimed Labs Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
VIVIMEDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.0 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Vivimed Labs reported weak Q3 FY26 results with standalone revenue from operations of ₹116.31 million, down sharply from ₹186.59 million in the previous quarter and ₹312.33 million in Q3 FY25. For the nine months ended December 2025, standalone revenue fell to ₹482.33 million from ₹810.29 million a year ago, a drop of about 40%. The company swung to a standalone loss before tax of ₹165.66 million in Q3 FY26 and a cumulative 9-month loss of ₹279.09 million, compared to a profit of ₹577.90 million in 9M FY25. Consolidated nine-month PAT was a loss of ₹293.49 million versus a profit of ₹198.05 million last year. The statutory auditor SVRL & Co. issued a qualified conclusion, flagging that the company has not provided for interest, penal interest and penal charges of approximately ₹164.52 million for the quarter (₹472.37 million year-to-date) on term and working capital loans, which understates liabilities and losses. The auditor also noted a pending evaluation of a forensic audit report from FY 2022-23 and insufficient evidence for a ₹46.03 million commission provision based on proforma invoices.
Negative for shareholders — sharp revenue decline, deep losses, and a qualified auditor report on understated liabilities and pending forensic audit findings raise serious concerns about earnings quality and financial health of the company.
| Q3 FY26 | Q3 FY25 | Change | |
|---|---|---|---|
| Revenue | ₹15.99 Cr | ₹36.51 Cr | −56.2% |
| Operating profit | −₹16.55 Cr | −₹6.04 Cr | loss widened |
| Profit after tax | −₹16.55 Cr | −₹5.98 Cr | loss widened |
| EBITDA margin | -68.3% | 2.9% | −71.2 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.